Oxyiminoalkanoic acid derivatives

Details Oxyiminoalkanoic acid derivatives Oxyiminoalkanoic acid derivatives

2005-08-02

2005-08-02

Shameem, Golam M M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S131000, C548S194000, C548S200000, C548S204000, C548S233000, C548S236000, C514S370000, C514S374000

Reexamination Certificate

active

06924300

ABSTRACT:
To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.A compound represented by the formula:wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, —CO—, —CH(OH)— or a group represented by —NR6— wherein R6is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, —SO—, —SO2— or a group represented by —NR7— wherein R7is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R2is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R3is a hydroxy group, OR8(R8is an optionally substituted hydrocarbon group.) or NR9R10(R9and R10are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R9and R10combine together to form a ring); R4and R5are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R4may form a ring with R2; provided that when R1is a ethoxymethyl, a C1-3alkyl, phenyl or p-methoxyphenyl and q=m=0, R3is NR9R10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

REFERENCES:
patent: 5563168 (1996-10-01), Brand
patent: 5750532 (1998-05-01), Girijavallabhan
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 6251926 (2001-06-01), Momose et al.
patent: 6495581 (2002-12-01), Momose et al.
patent: 0 075 805 (1983-04-01), None
patent: 0 075 805 (1983-04-01), None
patent: 0 233 780 (1987-08-01), None
patent: 0 233 780 (1987-08-01), None
patent: 0 370 629 (1990-05-01), None
patent: 0 370 629 (1990-05-01), None
patent: 0 400 805 (1990-12-01), None
patent: 0 400 805 (1990-12-01), None
patent: 0 506 149 (1992-09-01), None
patent: 0 506 149 (1992-09-01), None
patent: 0 581 187 (1994-02-01), None
patent: 0 708 098 (1996-04-01), None
patent: 0 708 098 (1996-04-01), None
patent: 0 916 651 (1999-05-01), None
patent: 0 916 651 (1999-05-01), None
patent: 1582029 (1980-12-01), None
patent: 59-167576 (1983-03-01), None
patent: 59-167576 (1984-09-01), None
patent: 62-77391 (1984-12-01), None
patent: 9-323929 (1996-04-01), None
patent: 9-323929 (1997-12-01), None
patent: 62-2077391 (1998-04-01), None
patent: 11-193272 (1999-07-01), None
patent: WO 96 02507 (1996-02-01), None
patent: WO 96/11183 (1996-04-01), None
patent: WO 96/33724 (1996-10-01), None
patent: WO 96 38427 (1996-12-01), None
patent: WO 96/40128 (1996-12-01), None
patent: WO 97 25042 (1997-07-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97 31907 (1997-09-01), None
patent: WO 98/05331 (1998-02-01), None
patent: WO 99/04815 (1999-02-01), None
B. Forman et al., “15-Deoxy-Δ12.14-Prostaglandin J2. . . ”Cell, vol. 83, pp. 803-812 (Dec. 1, 1995).
J. Lehmann et al., “An Antidiabetic Thiazolidinedione Is a High . . . ”J. Biol. Chem., vol. 270, 12953-12956 (Jun. 2, 1995).
T. Willson et al., “The Structure-Activity Relationship between . . . ”J. Med. Chem., vol. 39, pp. 665-668 (1996).
P. Tontonoz et al., “Terminal Differentiation of human liposarcom cells . . . ”Proc. Natl. Acad. Sci. USA, vol. 94, pp. 237-241 (Jan., 1997).
J. Lehmann et al., “Peroxisome Proliferator-activated Receptors . . . ”J. Biol. Chem., vol. 272, No. 6, pp. 3406-3410 (Feb. 7, 1997).
M. Ricote et al., “The peroxisome proliferator-activated . . . ”Nature, vol. 391, pp. 79-82 (Jan. 1, 1998).
C. Jiang et al., “PPAR-γ agonists inyhibit production . . . ”Nature, vol. 391, pp. 82-86 (Jan. 1, 1998).
Jiang, et al. “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines”Nature 391:82-6(Jan. 1998).
Ricote, et al. “The peroxisome proliferator-activated receptorγ is a negative regulator of macrophage activation”Nature391: 79-82 (Jan. 1998).
Lehmann, et al. “Peroxisome Proliferator-activated Receptors α and γAre Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”The Journal of Biological Chemistry272(6) 3406-10 (Feb. 7, 1997).
Tontonoz, et al. “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor”The National Academy of Sciences of the USA94: 237-241 (Jan. 1997).
Willson, et al. “The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones”Journal of Medicinal Chemistry39(3): 665-68 ((1996).
Lehmann, et al. “An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ)”The Journal of Biological Chemistry 270(22):12953-56(Jun. 2, 1995).
Forman, et al. “15-Deoxy-Δ. 12.-14-Prostaglandin J2Is a Ligand for the Adipocyte Determination Factor PPARγ”Cell83: 803-12 (Dec. 1, 1995).

Affiliated with

Also associated with

Rating

Oxyiminoalkanoic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxyiminoalkanoic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxyiminoalkanoic acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3523210